The US Food and Drug Administration (FDA) recently issued a final guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.” The guidance finalizes a 2020 draft guidance outlining how sponsors and investigators can legally conduct clinical trials for certain drugs containing cannabis or cannabis-derived compounds such as cannabidiol (CBD)....
By:
By: